Christopher M Juneau, PT, DPT, SCS, CSCS | |
Us Air Force/ Fort Carson, 8420 Skyraider Rd, Colorado Springs, AA 80913 | |
(318) 715-8415 | |
Not Available |
Full Name | Christopher M Juneau |
---|---|
Gender | Male |
Speciality | Physical Therapist - Sports |
Location | Us Air Force/ Fort Carson, Colorado Springs, Armed Forces Americas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326651498 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2251S0007X | Physical Therapist - Sports | PTL.0017179 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Christopher M Juneau, PT, DPT, SCS, CSCS 1340 Farnham Pt Apt 208, Colorado Springs, CO 80904-5202 Ph: (318) 715-8415 | Christopher M Juneau, PT, DPT, SCS, CSCS Us Air Force/ Fort Carson, 8420 Skyraider Rd, Colorado Springs, AA 80913 Ph: (318) 715-8415 |
News Archive
In a typical analytical workflow, 49% of out-of-specification (OOS) errors can be attributed to either sample processing steps or operator error. In addition, the sample processing steps account for 61% of the manual workload.
A study by Hospital for Special Surgery researchers has provided the first comprehensive look at just how metal-on-metal total hip replacements are failing in patients around the country.
Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.
DePuy Synthes Spine announced the global launch of "mPACT" (medialized Posterior Approach Cortical Trajectory), a program that combines implants, education, clinical research and procedural support for posterior mini open fixation and fusion procedures.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.
› Verified 4 days ago